AI imaging tools are moving from experimental to routine use, but misdiagnosis risk, bias, and opaque reasoning remain major concerns. Recent frameworks emphasize that clinicians must treat AI outputs as decision support, not automated verdicts, and should rely on validated performance, transparent explanations, and continuous bias monitoring before incorporating AI into clinical judgment [1][2].

Practical interpretation principles

1. Treat AI as an informed second reader, not an oracle

• Always cross‑check AI output against your own interpretation and clinical context.

• Use AI to highlight regions of interest, flag subtle patterns, or quantify findings, but let final judgment rest with clinical reasoning.

• Override when the AI conflicts with strong clinical/imaging evidence.

• Studies show clinicians often correctly override faulty AI but may also incorrectly override correct suggestions when trust is low; a structured approach to disagreement helps [1].

2. Require evidence of validation and scope of use

Before trusting an AI imaging tool:

• Confirm robust validation:

• External validation across multiple sites and demographic subgroups.

• Prospective or pragmatic trials demonstrating real‑world safety and performance—not only retrospective AUCs [1][2].

• Check key metrics:

• Discrimination: AUROC, sensitivity/specificity for your specific indication.

• Calibration: Does a “90% probability” truly correspond to ~90% event rate (e.g., low expected calibration error, good Brier score)? [2]

• Subgroup performance: Differences in false‑negative/false‑positive rates and AUC across age, sex, race, and site (ΔFNR, ΔAUC) [1][2].

• Understand intended use and limits:

• Which modalities, acquisition protocols, and populations were included in training/validation?

• Is it triage, detection, or characterization? Using a tool outside its labeled scope greatly raises error risk.

3. Use explanations as a safety layer, not a substitute for judgment

Modern guidance recommends a hybrid explainability approach:

• Saliency overlays + causal rationale:

• Non‑blocking overlays (e.g., heatmaps) highlight where the model is “looking,” paired with a short textual or symbolic rationale aligned with known imaging features [1][2].

• Verify that highlighted regions and stated features are anatomically and pathophysiologically plausible.

• Know the limits of LIME/SHAP and similar tools:

• They can reveal feature importance but are local, can be noisy, and may mislead in the presence of correlated features; treat them as hints, not proof [1].

• Prefer interpretable models when performance is similar:

• Frameworks suggest if an interpretable model is within ~0.01–0.02 AUC of a black box with similar calibration/fairness, use the interpretable model as primary [1][2].

4. Actively consider bias and fairness

• Ask for subgroup performance reports:

• Evidence shows higher misdiagnosis and false‑negative rates in minorities, those with darker skin in dermatology, rural populations for pneumonia, etc., when data are unbalanced [1].

• Adjust trust based on patient subgroup:

• If the vendor fact sheet or institutional reports show weaker performance for a given demographic, treat AI outputs for those patients as lower‑reliability and lean more heavily on human expertise.

• Flag and report suspected bias:

• If you see systematic miscalls in particular subgroups or scanners, report through institutional governance channels so drift and bias monitoring can respond.

5. Integrate into workflow in a time-efficient way

• Demand non‑disruptive interfaces:

• Explanations should be visible but not obstructive, taking <~1 minute to review per study [1][2].

• Document AI involvement:

• EHR entries should capture:

  • Model name and version.

  • Role of AI in the decision (triage assist, secondary read, measurement).

  • Whether AI was followed or overridden, especially for major findings.

• Use AI to improve consistency, not to replace double reading:

• For screening programs (e.g., mammography, chest CT for nodules), AI can standardize detection thresholds and reduce fatigue but should be part of a protocol that includes periodic human review of AI‑only negative cases.

6. Communicate transparently with patients

• Layered disclosure:

• Simple statement: “We used an AI tool to help review your images; I’ve reviewed its findings personally.”

• Offer a short “AI fact label” summarizing role, strengths, and limitations, including any known subgroup caveats [1][2].

• Respect preferences:

• Where policy permits, accommodate reasonable requests for human‑only review or second opinions when patients are uncomfortable with AI involvement.

Counterarguments and risk management

• Concern: AI may degrade skills and vigilance.

• Evidence suggests that over‑reliance can reduce detection of both normal and abnormal findings in some configurations [1]; countermeasures include:

  • Randomizing visibility of AI suggestions in QA studies.

  • Requiring independent initial reads in high‑risk contexts with AI used only as a check.

• Concern: Time burden of auditing AI.

• One study cited shows that auditing deep‑learning outputs can take more than twice as long as auditing rule‑based systems [1]. Systems should be redesigned to offer concise, high‑yield explanations, not overwhelming overlays.

Implications for doctors

• Treat AI outputs as hypothesis prompts.

• Rely on tools that show strong, externally validated performance with clear calibration and fairness profiles.

• Use interpretability tools to identify when the model is likely failing, especially in underrepresented groups.

• Demand institutional governance—bias monitoring, drift detection, and incident reporting—rather than bearing all risk individually.